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Background: Vitamin D is involved in a wide variety of biological processes including bone metabolism,
modulation of the immune response, and regulation of cell proliferation and differentiation. The present
study aimed to investigate vitamin D status and the genetic polymorphism BsmI (A/G) of vitamin D
receptor (VDR) among a group of Egyptian female patients with breast cancer.
Methods: The current study included 60 female patients diagnosed as breast cancer (BC) attending
Mansoura Oncology Center, Mansoura University, and 60 age-matched healthy control females. Serum
25(OH) vitamin D level was measured using Enzyme-linked immunosorbent assay (ELISA) kit. A poly-
merase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) method and frag-
ment analysis were performed to determine the VDR BsmI (A/G) polymorphism.
Results: 25(OH) vitamin D levels were significantly lower in the patients with BC (22.1 ± 10.9 ng/ml)
compared to controls (41.2 ± 11.22 ng/ml) (p 6 0.001). Vitamin D deficiency- insufficiency was reported
in 76.7% of BC patients and 20% of the controls (P 6 0.001, OR = 13.1, 95%CI = 5.5  31.4). Bb genotype
was statistically higher in the BC patients than in the healthy controls (P 6 0.001). 81.2% of BC patients
were of Bb genotype, 10.9% of BB genotype and 4.3% of bb genotype, while in controls, 33.3% for each
genotype. No statistically significant difference in allele frequency was observed between the two studied
groups. Carriers of Bb genotype had 4.6 times increased risk of developing breast cancer (95% confidence
interval of 2.0–10.3) when compared to other genotypes.
Conclusion: A significant association exists between vitamin D deficiency and the risk of breast cancer. B
allele or Bb genotype of VDR may be a susceptibility risk factor for BC development.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vitamin D both from dietary and endogenous sources under-
goes the first hydroxylation in the liver to form 25-
hydroxyvitamin D [25(OH)D]. A second hydroxylation takes place
in the kidneys and other tissues to form an active form of vitamin
D (1,25-dihydroxyvitamin D) [1,25(OH)2 D] [1]. Vitamin D regu-
lates calcium absorption in the small intestine and acts withparathyroid hormone to mediate bone mineralization and main-
tain calcium homeostasis in the blood. Studies have demonstrated
a relationship between low vitamin D levels and various diseases;
probably due to its anti-inflammatory and immune-modulating
properties [2].
Interestingly, an active form of vitamin D (1,25-
dihydroxyvitamin D) has been demonstrated to promote cell dif-
ferentiation and inhibit cell proliferation, affecting cancer risk via
binding to vitamin D receptor (VDR) [3]. VDR is expressed in many
types of cells, including normal and malignant breast cells [4].
Breast cancer is strongly affected by the hormonal environment.
Genetic variations responsive to hormonal activity are possible
contributors for increased risk. The genes involved in steroid hor-
mone metabolism and transport can act together to provide a
high-risk profile for breast cancer. Variations in these genes can
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interactions [5].
Breast cancer is the most common type of malignancy among
females in Egypt and worldwide where it represents 38.8% of the
total cancer incidence locally and 22.9% globally. In 2013, the esti-
mated number of cases in Egypt was 17,905 and was expected to
be triple by 2050 [6].
The autocrine/paracrine pathway of vitamin D biosynthesis has
an important role in breast cell carcinogenesis [7]. In this pathway,
circulating 25-OH vitamin D reaches the breast tissue to be con-
verted into its active form by endogenous 1-a-hydroxylase that
is present in the breast [7,8]. The locally produced active vitamin
D binds to VDR and regulates cell development [8].
VDR is an intracellular hormone receptor, belonging to steroid
hormone receptor family; it binds to 1,25(OH)2 D and interacts
with specific nucleotide sequences (response elements) of target
genes to produce many biological effects [9]. VDR gene lies on
the long arm of chromosome 12 (12q12-14) and has approximately
200 single nucleotide polymorphisms (SNPs) [10].
Common allelic variants have been identified in human VDR
gene with some of them having an essential risk for a variety of
diseases including breast cancer [11]. The best-studied SNPs
include a start codon polymorphism FokI (T/C) in exon II, BsmI
(A/G) and ApaI (C/A) polymorphisms in the intron between exon
VII and IX and a TaqI (T/C) variant in exon IX. These SNPs are
strongly linked with a singlet (A) repeat in the 30-untranslated
region of the gene that may influence VDR mRNA stability [12].
The present study has been conducted to compare vitamin D
status as well as VDR BsmI (A/G) polymorphism in a group of
Egyptian female patients with BC and age matched healthy control
subjects.2. Subjects and methods
2.1. Subjects
The present study included 120 participants: 60 female patients
diagnosed as breast cancer admitted at Mansoura Oncology Center,
Mansoura University,and 60 healthy age-matched females free of
any benign or malignant breast diseases as a control group.
Exclusion criteria were: chronic renal disease, liver disease,
hyperthyroidism, malabsorption syndrome, patients taking drugs
as anticonvulsants, glucocorticoids, immunosuppressant and
intake of vitamin D within the last six months.
2.1.1. Diagnosis of breast cancer patients
Included patients were assessed by clinical examination, radio-
logical examination by either ultrasonography or mammography
for the breast mass in addition to adequate metastatic work up
and the preoperative histopathological diagnosis was made via tru-
cut biopsy or fine needle aspiration cytology. However, the study
group preferred to rely on the tumor characteristics stated in the
final postoperative histopathology records for the patients who
were treated surgically. The study was approved by the Research
Ethics Committee (REC) for the experimental and clinical studies
at the Faculty of Medicine, Mansoura University, Mansoura, Egypt,
Code number: R/16.03.116. The work has been carried out in accor-
dance with the Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments in humans. All patients
and healthy controls signed informed consent forms.
2.2. Sampling
A sample of five ml venous blood was withdrawn from the can-
cer patients and the healthy controls under complete aseptic con-ditions. One ml was added to EDTA containing tube for DNA
extraction, and the remaining blood was added to a plain tube
without anticoagulant, left for 10 minutes at room temperature
to clot, and then serum was separated and stored at 20 C until
the time of assay of 25(OH) vit. D.
2.3. Anthropometrical measurements
Height and weight were measured, and then body mass index
(BMI) was calculated as body weight divided by height squared
(kg/m2).
2.4. Measurement of serum levels of 25(OH) vitamin D
Serum 25(OH) vitamin D levels were measured using Enzyme-
linked immunosorbent assay (ELISA) kit supplied by DRG, Division
of DRG International, Inc. Fauenbergstr.18, D-35039Marburg,
Germany.
Deficient/Insufficient subjects were defined as those having
levels less than 30 ng/ml, while the sufficient ones were those with
levels greater than30 ng/ml [13].
2.5. Determination of genetic polymorphism BsmI (A/G) of VDR
DNA was extracted from whole blood samples collected on
EDTA using the Gene JET whole blood genomic DNA Purification
Mini Kits (Thermo Scientific, lot 00138029, Lithuania, EU). The
BsmI VDR polymorphism is located within intron 8 of the gene.
It was determined using polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) analysis [14].
Genomic DNA from cases and controls was subjected to PCR
analysis of VDR gene using the following primers for BsmI poly-
morphism; forward primer: 50-CAACCAAGACTACAAGTACCGCGT
CAGTGA-30 and the reverse one: 50-AACCAGCGGGAAGAGGT
CAAGGG-30.The reaction mixture contained 10 ll DNA templates,
3 ll of each primer, 25 ll master mix (Fermentas, Germany lot
00141171), 9 ll sterile high-quality water.
Reaction conditions were carried out in thermocycler PTC-100
(Biorad, USA) with the following cycling parameters: an initial
94 C for 10 min followed by 35 cycle of 94for 55 s (seconds)
(denaturation), 66 C for 70 s (annealing) and final extension at
72 C for 10 minutes.
The resulting 800 base pair (bp) PCR product is then digested
with BsmI at 65 C for 18 h using 5 units of enzyme (Boehringer
Mannheim, Penzberg, Germany) per 20 ll reaction. Following
digestion, the DNA fragments were separated using 2% agarose
gel containing ethidium bromide then, visualized under short-
wave UV light and compared to those of DNA ladder run at the
same time. DNA from homozygote individuals (BB) lacking a BsmI
restriction site appeared on the gel as a single 800 bp band. DNA
from homozygote individuals (bb) appeared as two well-
separated bands, 650 and 150 bp, indicating that the BsmI enzyme
site is present in both alleles. Heterozygotes (Bb) have three bands:
a 650 bp band and a 150 bp band (representing the presence of the
BsmI site in one allele) plus an 800 bp band (indicating its absence
in the other).
2.6. Statistical analysis
The statistical analysis of data was conducted using the SPSS
(Statistical package for social science) program (SPSS, Inc, Chicago,
IL) version 20. Qualitative data were presented as number and per-
centage. Chi-square and Fisher’s exact tests were used to compare
groups. Quantitative data were presented by mean, SD (standard
deviation). For comparison between two groups; student
t-test was used. Deviations from Hardy–Weinberg equilibrium
Table 2










Bb 39(81.2) 9(64.3) 3.1(0.7–12.0)
BB 5(10.9) 4(28.6) 0.3(0.1–1.3)
bb 2(4.3) 1(7.1) 0.5(0.05–7.0)
Allele
b 43(46.7) 11(39.3) 1.36(0.6–3.2)
B 49(53.6) 17(60.7) r(1)
Non-BC
Genotype
Bb 4(33.3) 24(50.0) 0.5(0.1–1.9)
BB 4(33.3) 11(22.9) 1.7(0.4–6.7)
bb 4(33.3) 13(27.1) 1.3(0.3–5.3)
Allele
b 12(50) 46(56.9) 1.1(0.4–2.7)
B 12(50) 50(43.1) r(1)
r = reference group, OR = odds ratio, CI = Confidence interval.
BC = Breast Cancer, Non-BC = Non Breast Cancer.
R.R. Elzehery et al. / The Egyptian Journal of Medical Human Genetics 18 (2017) 269–273 271expectations were determined using the Chi-squared test. Odds
ratio and 95% confidence interval were calculated. P 6 0.05 was
considered statistically significant.
3. Results
The study groups were matched regarding their age with
an average age of (48.2 ± 13.2 years) for patients and
(44.9 ± 11.22 years) for controls (P = 0.18).
Serum 25(OH)vit D level was significantly lower in the BC
patients (22.1 ± 10.9 ng/ml) compared to healthy controls
(41.2 ± 11.22 ng/ml) (P 6 0.001) (Table 1), with 76.7% of the BC
patients found to be (deficient/insufficient), while only 20% of the
controls were (deficient/insufficient) with (P 6 0.001, OR = 13.1,
95% CI = 5.5–31.4).
Except for BMI (FET, P = 0.04) and metastasis (FET, P = 0.009),
there was no statistically significant correlation between all stud-
ied variables (Table 3) and the hypovitaminosis D status in BC
patients.
There was no deviation from the expected Hardy-Weinberg
equation for the BsmI genotypes in the control group (P = 0.6).
Analysis of the distribution of VDR BsmI polymorphism demon-
strated that, the heterozygous Bb genotype was statistically higher
in the BC patients than in the healthy controls (P 6 0.001). No sta-
tistically significant difference in allele frequency was observed
between the two studied groups (P = 0.3) (Table 1).
Distribution of VDR BsmI genotypes in both cancer patients and
controls who were deficient in vitamin D is illustrated in Table 2;
in BC patients, 81.2% were of Bb genotype, 10.9% of BB genotype
and 4.3% of bb genotype, while in controls, 33.3% for each
genotype.
Analysis of the Odds ratio of the BsmI SNP of VDR revealed that,
carriers of Bb genotype had 4.6 times increased risk of developing
breast cancer with 95% confidence interval of (2.0–10.3) when
compared to other genotypes (Table 2).
4. Discussion
The current study shows that among the studied groups of
Egyptian female subjects, vitamin D deficiency was more common
in patients with BC as compared to the age-matched control group,
indicating a strong association between breast cancer risk and
serum levels of vitamin D. Although 1,25-dihydroxyvitamin D is
the active form, it is widely accepted that the measurement
of circulating 25(OH) D provides better information on patientsTable 1
Vitamin D status, serum levels & VDR BsmI polymorphism of the studied groups.














H.W. equation = Hardy Weinberg equation.
r = reference group, OR = odds ratio, CI = Confidence interval.
* P is significant if 6 0.05.
** Cut-off point = 30 ng/ml13.vitamin D status and allows its use in the diagnosis of hypovita-
minosis [12].
These results are supportive of the association between vitamin
D and the risk of breast cancer. The results of the current study are
consistent with those reported by Imtiaz et al. [15] who showed
that vitamin D deficiency was observed in 95.6% of Indian patients
with breast cancer versus 77% in the control group (P < 0.001). Low
circulating levels of 25(OH) vitamin D is hypothesized to decrease
the local production of 1,25(OH) 2 D within the breast tissue
increasing the risk of developing BC [16]. This can be explained
by that, low circulating levels of 25(OH) D decreases the availabil-
ity of the substrate for 1a-hydroxylase expressed within the breast
tissue and responsible for autocrine/paracrine synthesis of 1,25
(OH)2D3 [16].
Lowe et al. observed that low levels of circulating 25(OH) D,
either alone or in combination with BsmI VDR genotype, may
increase the risk of breast cancer in a UK Caucasian population
[17]. Conversely, Bertone-Johnson et al. stated that such associa-
tion is insignificant [18].
Studies have also shown that women with serum levels of 25
(OH) vitamin D more than 50 ng/ml had a 50% lower risk of devel-
opment of breast cancer as compared to those with serum levels
less than 30 ng/ml [18–20].controls N(%) Statistical test & significance OR(95% CI)
) v2 = 38.6, 13.1(5.5–31.4)
) P 6 0.001* 1 (r)
1.22 t = 9.5, P 6 0.001*




) v21.1, P = 0.3 0.7(0.5–1.3)
)
Table 3
Factors associated with hypovitaminosis D in BC patients other than BsmI genotype.
The parameter Total Hypovitaminosis D N(%) Significance
Cancer stage
1&2 39 29(74.4)
3&4 21 17(81.0) FET, P = 0.75
Type
IDC 48 36(75.0)
Others 12 10(83.3) FET, P = 0.7
BMI
Overweight 10 5(50.0)
Obese 50 41(82.0) FET, P = 0.04*
Marietal status
Single 1 1h1 0 0i
Married 59 45(76.3) FET, P = 1.0
History of breast disease
No 46 36(78.3) FET, P = 0.7
Yes 14 10(71.4)
History of breast cancer
No 51 41(80.4) FET, P = 0.2
Yes 9 5(55.6)
Menopausal status




Yes 5 1(20.0) FET, P = 0.009*
Skin complexion
White 39 29(74.4)
Black 21 17(81.0) FET, P = 0.75
Dressing style
Hijab 44 36(81.8)
Niqab 16 10(62.5) FET, P = 0.17
Milk intake
No 37 27(73.0)
Yes 23 19(82.6) v2 = 0.7, P = 0.5
Daily sun exposure
No 25 19(76.0)
Yes 35 27(77.1) v2 = 0.01, P = 0.9
OCP
No 36 28(77.8)
Yes 24 18(75.0) v2 = 0.1, P = 0.8
HRT
No 45 33(73.3)
Yes 15 13(86.7) v2 = 1.1, P = 0.5
Multivitamin intake
No 54 40(74.1)
Yes 6 6(100) FET, P = 0.2
BMI: Body mass index, OCP: Oral contraceptive pills, HRT: Hormonal replacement
therapy, FET: Fisher’s exact test.
* P is significant if 6 0.05.
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estrogen pathway by down-regulation of the estrogen receptor
(ER) decreasing the oestrogenic bioresponses such as cell growth
[21]. Additionally, vitamin D has been linked to promoting cellular
differentiation, decreasing tumor cell growth, stimulating apopto-
sis, and reducing angiogenesis [22].
The current study demonstrated that VDR genotype distribu-
tions were different in the two studied groups regarding BsmI
SNP (v216.6, P 6 0.001). Genotype Bb was over-expressed in 80%
of patients with BC, in comparison to 46.7% in the healthy con-
trols(OR: 4.6, 95%CI: 2–10.3); with decreased presentation of the
other two genotypes in patients as compared to controls (15% for
BB, 5% for bb in patients versus 25%, 28.3% in controls, respec-
tively). Consequently, it could be hypothesized that Bb genotype
is considered a risk factor for developing BC independent of vita-
min D level and status as no significant relation observed between
vitamin D levels and VDR BsmI genotypes.
Inspite of no statistical significant difference between the two
studied groups as regard allele frequency (v21.1, P = 0.3) with
[OR = 0.7, 95% CI (0.5–1.3)], patients with B allele carried a higher
risk for BC development than the b allele.The results of other studies investigating the association
between VDR BsmI polymorphism and BC risk are inconsistent.
Positive associations were reported by Bretherton-Watt et al.
[23], and Guyet al. [24], in Caucasian subjects in the UK; showing
that bb genotype was significantly over-represented in patients
with BC. Similarly, a Japanese study identified that bb genotype
was the most common genotype in the patient group with almost
4-fold increase in the risk of BC [25]. Furthermore, a recent meta-
analysis suggested the same findings [26–30]. Two other studies
reported a significantly increased risk for the BB carriers; one car-
ried out on Hispanic population [31] and the other on Taiwanese
population [32].Contrarily, a meta-analysis by Zhang and Song
[9] showed no significant association between the BsmI polymor-
phism and BC risk.
These studies were carried out on different populations as Afri-
can American, French Canadian and southwestern American popu-
lations [10,32–39]. The difference in ethnogenetic background
between the Egyptian females and the other studied populations
could partly explain the differing results.
The present study suggested that vitamin D level is a risk factor
for BC development independent of different VDR BsmI genotypes.
Indeed, the present study reported an association between the
hypovitaminosis D status in patients with BC and BMI (FET,
P = 0.04) and metastasis (FET, P = 0.009). Previous studies showed
that vitamin D deficiency is an independent risk factor for abdom-
inal obesity in women [40]. Consistently, the expression levels of
the 25-hydroxylase and the 1a-hydroxylase have been shown to
be decreased by 71% and 49%, respectively, in the subcutaneous
adipose tissue of obese subjects suggesting that the adipose tissue
can metabolize vitamin D locally [41].
In conclusion, the current study shows a significant association
between vitamin D deficiency and the risk of breast cancer among
Egyptian females. We also report that B allele or Bb genotype may
be susceptibility risk factors for BC development and that b allele
may be protective independent of vitamin D levels. Larger
population- based studies are warranted to confirm these results.Conflicts of interest
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